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Abstract Dendritic cells (DCs) lie at the heart of the innate
immune system, specialised at recognising danger signals in
many forms including foreign material, infection or tissue
damage and initiating powerful adaptive immune and inflam-
matory responses. In barrier sites such as the lung, the instru-
mental role that DCs play at the interface between the envi-
ronment and the host places them in a pivotal position in
determining the severity of inflammatory disease. The past
few years has seen a significant increase in our fundamental
understanding of the subsets of DCs involved in pulmonary
immunity, as well as the mechanisms by which they are acti-
vated and which they may use to coordinate downstream in-
flammation and pathology. In this review, we will summarise
current understanding of the multi-faceted role that DCs play
in the induction, maintenance and regulation of lung immu-
nopathology, with an emphasis on allergic pulmonary disease.
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Dendritic cells (DCs) are critical innate immune cells at barrier
sites, including the lung, playing a decisive role in initiation of
adaptive immune responses against foreign material, infec-
tion, commensals or tissue damage [1]. Of all antigen present-
ing cell (APC) types in the body, DCs are particularly adept at
recognising such dangers, migrating from the periphery to the
lymphatics, and activating naïve CD4+ and CD8+ T cells [2].
While the discussion as to what truly distinguishes DCs from
other mononuclear phagocytes continues in some circles,
most researchers would agree that functional rather than phe-
notypic definition of DCs is the key. In this review, in line with
the general consensus [1], we define as ‘DCs’ any mononu-
clear phagocyte that has the ability to take up antigen (Ag),
process it for presentation on MHC-I or II, migrate to the
nearest draining lymph node (dLN) and efficiently and effec-
tively activate and polarise naïve T cells. Their crucial role in
this regard is clearly illustrated by the fact that people with
genetic defects resulting in a lack of DCs, or mice wherein
DCs are experimentally depleted, suffer from severely im-
paired adaptive T and B cell responses and increased suscep-
tibility to a wide range of infections [3, 4]. This role as the
preeminent cell type in the body for activation and modulation
of adaptive responses, and in determining the balance of ef-
fector cell vs. regulatory responses, is central to understanding
the normal progression of protective immunity in most situa-
tions. As clonal expansion of adaptive immunity can directly
amplify or regulate immunopathology, consideration of this
key role of DCs in maintaining health in the lung is key.
The allergy epidemic and allergic pulmonary disease
As a mucosal barrier site, the lung is continually exposed to a
wide variety of challenges that can trigger immune responses
that, when inappropriate or unbalanced, can cause immuno-
pathology. Such responses underpin respiratory disease and
are a significant cause of illness andmortality worldwide, with
allergic responses leading to asthmatic disease having a dra-
matic impact on global health [5–7]. Immune mechanisms
underlie allergic disease and the pathology associated with
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allergies, typified by a defined range of cell types and patho-
logical responses. These include activation and/or recruitment
of a variety of characteristic innate and adaptive immune cells,
as well as induction of a range of distinctive physiological
processes that together are sometimes termed as ‘type 2 in-
flammation’ [8].
In the lung, type 2 inflammatory mechanisms can result in
allergic asthma, currently thought to be the predominant cause
of asthma in children, and in approximately 50% of adults [9].
Acute symptoms of asthma include wheezing, coughing and
shortness of breath, characterised as airway hyperreactivity
(AHR), that can be life threatening. Over time, chronic pul-
monary type 2 inflammation can lead to damaging fibrotic
pathology and leave individuals at increased risk of secondary
pulmonary infections or chronic obstructive pulmonary dis-
ease (COPD). Immunological hallmarks of allergic asthma
include eosinophilia in patient bronchoalveolar lavage
(BAL) fluid, sputum or bronchial biopsies, Th2 polarised
CD4+ T cells secreting type 2 cytokines (including IL-4, IL-
5 and IL-13), and IgE antibody. However, in recent years, as
patient stratification approaches have become more refined, it
has become clear that asthma is not a single disease and that
individuals with asthma can be further classified into distinct
groups or ‘endotypes’ [10]. In particular, not all asthmatics
present ‘classical’ eosinophilic/type 2 disease, with some pa-
tients instead displaying disease that is more dominated by
neutrophils and insensitive to steroid treatment [11, 12]. As
type 2 (eosinophilic) and type 17 (neutrophilic) inflammation
are thought to be governed by different cellular and molecular
mechanisms [13], this may help explain the modest levels of
success so far of therapies that have tried to target type 2
inflammatory mediators for all asthma patients. Implicit in
these processes is the character of the immune and inflamma-
tory response that an individual develops, which directly im-
pacts the type and severity of resulting immunopathology.
Type 2 inflammation is a characteristic of allergic inflam-
mation, but also of parasitic helminth (worm) infection
[14–16]. The effector cell types and mechanisms at play in
both allergic and helminth infection settings appear to be very
similar, being dominated by eosinophilia, CD4+ Th2 cells,
alternatively activated macrophages and GATA3+ type 2 in-
nate lymphoid cells (ILC2s). However, it could be argued that,
while the type 2 response against parasitic worms has likely
evolved ‘appropriately’ to enable the host and parasite to co-
exist effectively, the response against allergens is likely an
aberrant or ‘inappropriate’ overexuberant response to foreign
material that is not inherently dangerous [17, 18]. Related to
this, the type 2 response against worms has also likely evolved
to heal tissue damage associated with migration of these often
large multicellular organisms through the body, as rapidly and
effectively as possible [19–21]. Further, when dysregulated,
these very same healing mechanisms can lead to damaging
fibrotic pathology [22].
Type 17 inflammation is more characteristic of fungal in-
fection, and typified by neutrophilia and CD4+ Th17 cells
with the ability to make a distinctive range of cytokines, in-
cluding IL-17A (which we will refer to as IL-17) [23].
Remarkably, although there are numerous triggers of asthma
that are abundant in the environment such as pollution, aller-
gens such as house dust mite (HDM), animal dander, pollen
and fungal spores, of the 0.5 million deaths attributed to asth-
ma each year worldwide, 50 % may have fungal asthma
(GAFFI, 2016). Intriguingly, fungi have the capacity to stim-
ulate both type 2 and type 17 inflammation that may or may
not confer immune protection [24–29]. As such, fungal aller-
gens may be of particular interest in trying to understand the
mechanisms that dictate the balance of type 2 and type 17
pulmonary disease.
DC activation and induction of adaptive immunity
in the lung
DCs reside throughout the lung tissue, underlying the epithe-
lial layer, poised to encounter foreign material, infections or
tissue damage. In this role, they are aided by their ability to
actively sample the airways [30]. Although present at low
numbers, DCs are highly sensitive to their environment, ex-
pressing a variety of pattern recognition receptors (PRRs) in-
cluding toll-like receptors (TLRs), C-type lectin receptors
(CLRs) and Nod-like receptors (NLRs). Through these recep-
tors, they are able to sense a wide range of pathogen, microbe
or damage-associated molecules, ranging from bacterial, viral,
fungal and protozoal commensals and pathogens through to
allergens, particles and pollutants. Additionally, the pulmo-
nary environment presents some unique features relative to
other barrier sites, such as specific surfactants and mucins,
which can also influence DC activation and function.
Importantly, the combination of PRRs engaged can tailor the
developing immune response by directly influencing the acti-
vation and function of DCs.
The influence of other innate cells on pulmonary DCs
As well as responding to these environmental stimuli directly
through PRR engagement, DCs can also be indirectly activat-
ed by other innate cells in the local environment. The pulmo-
nary epithelium is a complex tissue, consisting of a variety of
epithelial cell (EC) types including ciliated ECs, goblet cells
and Clara cells which vary in composition and distribution
depending on their location within the lung [31, 32]. While
each of these cell types can act in their own right as innate
protection against barrier disruption, infection and damage,
their interaction with DCs can also alter the developing adap-
tive immune response [31]. A range of EC mediators and
cytokines, in particular IL-25, IL-33 and thymic stromal
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lymphopoietin (TSLP), is thought to be important for condi-
tioning of DC activation and function and for Th2 induction
[33]. In addition, EC-derived endogenous danger-associated
molecular patterns (DAMPS) such as ATP [34] and uric acid
[35] can also impact DC activation and function in the lung,
being triggered in by allergens such as HDM, with the balance
of these signals being crucial for mediating allergic inflamma-
tion. Though less is known about the role of EC-derived cy-
tokines in the context of neutrophilic asthma, recent evidence
confirmed that EC TLR4 expression can mediate eosinophil
inflammation in the airways, yet is dispensable for neutrophil
influx, which instead depends on haematopoietic TLR4
sources [36]. Furthermore, IL-17 can directly trigger ECs to
induce recruitment of neutrophils via CXCL1 [37].
The identity of which specific EC types produce which
combinations of mediators in type 2 and type 17 settings,
and how this specificity may be selectively controlled, is
only beginning to be defined at mucosal sites [38].
Related to this, while EC recognition of endotoxin (bac-
terial lipopolysaccharide) present in the lung via TLR4
promotes allergic responses [39], chronic exposure to
LPS modulates EC responses and dampens DC ability to
induce allergic inflammation against HDM [40]. This is a
key point, as the lung contains a stable microbiome that is
dysregulated during allergic inflammation [41–43].
Further, gnotobiotic mice display exacerbated allergic in-
flammation [44] and neonatal mice that are yet to estab-
lish a diverse microbiota mount enhanced allergic re-
sponses to HDM, with the microbiota inducing DC toler-
ance to allergens [45]. The relevance of this has been
demonstrated that exposure to high bacterial environments
such as farms in childhood reduces the risk of allergy and
asthma [46].
Much less is known about the role of endothelial cells in
these processes, though it is clear that angiogenic remodelling
is a feature of asthma [47]. It seems likely that they will be
heavily involved in settings where danger signals reaching the
lung are blood-borne, influencing the migration of immune
cells such as eosinophils to and from the lung tissue site [48].
ILCs comprise a diverse grouping of subsets, distinguished
based on the transcription factors they express and the cyto-
kines they produce [49]. Although some agreement now exists
in terms of ILC genealogy and diversity, vigorous debate still
surrounds discussion of their relevance in most settings.
Present in very small numbers in the lung, ILC2s expand in
response to allergic stimuli and EC production of cytokines
such as TSLP and IL-33 [50] and TGFβ1 [51]. ILC2s can
clearly produce large amounts of IL-13 in particular which,
in addition to directly impacting pathology, may feed back to
influence activation, cytokine/chemokine production and mi-
gration of DC subsets from the lung [52, 53]. In this context,
the epidermal growth factor (EGF)-like cytokine
amphiregulin (AREG), which can be produced in substantial
quantities by ILC2s, has been linked to a variety of outcomes
that could directly or indirectly influence immunopathology in
the lung [54]. Compared to ILC2s, less is known about how
ILC3s may influence development of neutrophilic airway in-
flammation through production of cytokines such as IL-17. A
recent study found that obese mice spontaneously developed
AHR with significant numbers of CCR6+IL-17+ ILC3s and
identified ILC3s in the BAL fluid of asthma patients [55]. It
remains to be determined what triggers ILC3 recruitment dur-
ing asthma, as well as what impact they have on DC ability to
promote allergic airway inflammation.
Other innate cell types that can influence developing im-
munopathology in the lung via their impact on DC activation
and function include granulocytes such as eosinophils, baso-
phils and mast cells. For example, eosinophils can impact DC
activation and type 2 induction through their degranulation
and secretion of granule components such as the alarmin
eosinophil-derived neurotoxin or eosinophil peroxidase [56,
57]. Basophils in particular, though dispensable for Th2 in-
duction per se, have been suggested to provide an important
accessory cell role as sources of IL-4 in supporting chronic
type 2 inflammation [58–61].
DC coordination of innate and adaptive inflammation
in the lung
Depending on the combination of the above factors - PRR
engagement, the influence of other innate cells types and the
unique lung environment - the outcome will be DC activation
or ‘maturation’ to express a diverse array of surface molecules
or mediators that can dramatically influence lung disease de-
velopment (Fig. 1). The secretion of proinflammatory or
antiinflammatory cytokines in response to local activating
triggers is the initial, and often overlooked, innate mechanism
by which DCs can exert influence over immunopathology in
the lung in the very early stages of infection or tissue damage.
Although present in very low numbers in the tissues, cytokine
production per cell can be substantial [2]. In this way, DCs can
rapidly produce high levels of proinflammatory cytokines
such as IL-12, TNFα and IL-6 in response to PRR ligands,
and in doing so, dramatically shape the character of the local
inflammatory environment. For example, DC-derived IL-12
can act directly on NK cells to trigger their activation and
IFNγ production in what could be deemed a ‘bystander’ fash-
ion [62].
However, the main mechanism by which DCs impact im-
munopathology in any setting, including the lung, is through
their potent ability to activate and influence adaptive arms of
the immune system. Following their activation in the lung, DC
migration to the mediastinal LNs enables them to interact with
and activate naïve T cells that, through rapid clonal expansion
and generation of effector cells that produce high levels of
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cytokine, and immunological memory, can have a major in-
fluence over developing and chronic immunopathology.
Effector and memory Th2 cells can exert a range of path-
ological outcomes in the lung, primarily through the impact of
the cytokines they produce. These include granulocyte recruit-
ment, goblet cell hyperplasia (leading to mucus overproduc-
tion) and bronchoconstriction [63–65]. Type 2 cytokines, and
in particular IL-13, have been proposed to narrow airways in
vitro and in vivo by triggering expression of the small GTPase
RhoA, which drives muscle contraction [66]. However, other
work involving cell-specific deletion of IL-4Rα on airway
smooth muscle cells has proposed that muscle constriction
in type 2 airway inflammation can occur independently of
IL-13 [67]. In addition, in asthmatic airways, long-term in-
flammation results in a dysregulated wound healing response,
which causes extensive collagen deposition and subepithelial
Fig. 1 Key players in type 2/type 17 pulmonary inflammation and
immunopathology. a The lung is continually exposed to a variety of
signals that can trigger immune responses. In a healthy lung, exposure
of epithelial cells (ECs) to danger signals triggers damage responses and
the release of tissue factor cytokines such as TSLP IL-25 IL-33 and
TGFβ [39, 50, 51, 173]. Simultaneously, antigens/allergens from the
airspaces directly activate dendritic cells (DCs) located in the lung
mucosa under the epithelial barrier [59, 86, 126]. The tissue factors
released by the epithelium can not only influence the DCs directly but
also indirectly via other innate cells such as innate lymphoid cells (ILCs)
to alter DC activation or migration and promote allergic inflammation
[52, 53]. Activated DCs can secrete a variety of proinflammatory
mediators such as IL-6 and TNFα that may influence other innate cells
in the lung such as intersitial macrophages (MΦs). Simultaneously, these
DCs can also secrete regulatory cytokines such as TGF-β, promoting the
generation of inducible regulatory T cells (iTregs) [152]. DCs then
migrate to the draining lymph node (LN) via CCR7 to prime and
polarise Th2, Th17 and iTreg cells, a process that may be assisted by
cytokine production by accessory cells such as ILCs. The mechanism(s)
by which this is achieved, and how these responses are balanced, is not
yet clear. b During chronic exposure to inflammatory signals from
antigens/allergens and/or innate cells, DCs release chemokines such as
CCL17 and CCL22 to recruit effector Th2 and Th17 cells to the lungs,
promoting the type 2/type 17 allergic inflammatory environment. It is
unknown the extent to which DCs collaborate with other innate cells
such as ILCs in the activation of recruited T cell populations, or innate
effector cells such as granulocytes (MC; mast cells, Bas; basophils, Eos;
eosinophils) and MΦs, to maintain chronic type 2 or type 17 inflammation
in the lung. In type 2 settings, this process is also influenced by B cells
releasing IgE that can bind to FcR-expressing innate cells. In contrast, type
17 responses promote neutrophil (Neut) infiltration, which may also impact
activation and function of innate effector populations such asMΦs [174]. In
both type 2 and type 17 settings, solublemediators from innate and adaptive
effectors can then mediate disease features such as goblet cell (GC) hyper-
plasia and smooth muscle (SM) contraction [63–65, 78]. Thus, DCs play a
central role in promoting or regulating chronic pulmonary disease (1)
through their central ability to initiate and direct primary responses and
(2) through influencing effector cell recruitment and activation during on-
going inflammation. They achieve this through cross-talk with a diverse
range of innate and adaptive effector populations, via production of soluble
mediators and/or direct cell contact. Defining the specific DC subsets in-
volved and the precisemechanisms they employ to communicatewith these
diverse effector cells, and how this changes over the course of chronic
inflammatory disease and in different disease settings, will reveal new
avenues for therapeutic intervention
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fibrosis that involves cytokines such as IL-10 and IL-13 [68].
Further, as well as their direct roles in pathology, some of these
Th2-driven outcomes feedback to affect ongoing DC function.
For example, the mucin Muc5B has been shown to influence
DC maturation in the context of tumour cells [69], though
more work is needed to determine how goblet cell hyperplasia
and mucins influence DCs to shape allergic inflammation in
the lung.
As introduced above, it is increasingly clear that asthma is a
broad spectrum of disease and some patients develop a more
type 17-associated disease, with dominance of neutrophils
rather than eosinophils [70], along with steroid resistance
[71]. Several different cellular sources of IL-17 have been
implicated in lung inflammation, including Th17 cells, γδ T
cells, ILCs and even macrophages [72]. The situation is clear-
ly more complex than originally thought, and the mechanisms
that determine type 2/type 17 coexistence and balance during
lung allergic inflammation are only beginning to be identified.
The ability of core elements of type 2 inflammation such as
IL-4 [73, 74] or ILC2s [75] to regulate IL-17 is well docu-
mented. In contrast, and somewhat counterintuitively, IL-17
may actually promote type 2 responses in some settings [76],
including allergic lung inflammation [77]. This suggests a
sequential situation where IL-17 may initially promote some
aspects of type 2 inflammation, only to be downregulated by
type 2 mechanisms once they have established. In addition,
IL-17 may be able to directly trigger lung smooth muscle
contraction during asthma [78]. More recently, evidence of
products of alternatively activated macrophages such as the
chitinase-like molecule Ym-1 promoting lung neutrophilia in
a type 2 context highlights the complexity of allergic lung
pathology [79]. It seems likely that the factors involved in
determining the type 2/type 17 balance will be complex and
context-dependent. Given that DCs are centrally involved in
promotion or regulation of both type 2 and type 17 inflamma-
tion, it is likely they will play a decisive role in determining
this balance.
How and where do DCs influence pulmonary T cell
activation?
DCmigration from the lung to the LNs is a process thought to
require upregulation of the chemokine receptor CCR7 and
responsiveness to the chemokines CCL19 and 21, which di-
rect DCs to the regions of the LNs where they can interact
with and activate naïve Tcells [80, 81]. Once this interaction is
initiated, DCs provide naïve T cells with several important
activating signals [2]. The first (‘signal 1’) requires presenta-
tion of antigenic peptide to CD4+ or CD8+ T cells in the
context of MHC-II or MHC-I, respectively. At this stage, the
affinity or avidity of MHC/Ag for a particular T cell receptor,
and the concentration or dose of Ag, can alter the ‘strength’ of
activating signal delivered to the responding T cell [82].
Recent development of techniques such as multiphoton mi-
croscopy has highlighted the importance of the strength or
duration of DC/T cell interaction for naïve T cell activation
and polarisation [83]. The second (‘signal 2’) provides
costimulation and survival signals to the responding T cell,
for example through CD80 or CD86 interaction with T cell
CD28. DC provision of signal 1 with inadequate levels of
signal 2 can lead to T cell anergy or hyporesponsiveness,
rather than activation and clonal expansion, and so is a key
step in T cell activation and generation of functional immuni-
ty. In addition to these fundamental DC/T cell interactions,
further factors at the time of T cell activation termed ‘signal
3’ can influence the polarisation of the T cells [84]. Signal 3
generally refers to cytokines produced by DCs that directly
influence the naïve CD4+ T cell polarisation process, such as
IL-12 promotion of Th1 development through T-bet induction
and stabilisation. In addition to providing survival and activa-
tion signals, some costimulatory molecules may also act to
influence T cell polarisation or function, as has been proposed
for CD70 during Th1 induction [85]. Thus, it is the combina-
tion of the type and level of expression of signals 1, 2 and 3, all
‘encoded’ in DCs by the nature of stimulus they have encoun-
tered in the lung, that is the major determining factor in their T
cell activation and polarising ability in the LNs.
For type 2 immunity, this process likely involves the help
of cytokines derived from accessory cells such as ILC2s or
basophils, while cells such as ILC3s could conceivably assist
DCs in Th17 induction, though this has yet to be shown. In
addition, CD4+ T cells activated by DCs provide help via
costimulation and cytokine production to B cells to dramati-
cally impact their activation and antibody production. During
allergic asthma, type 2 cytokines (particularly IL-4) induce
high level IgE production by B cells that can then exert a
systemic influence over granulocyte activation in the lung,
for example through Fc receptor cross-linking and sensitisa-
tion of mast cells leading to heightened release of pathological
mediators such as histamine. The cumulative result is clonal
expansion of antibody producing B cells along with effector T
cells that can then leave the LN andmigrate back to the lung to
exert their influence over the pathological processes at play.
Indeed, it has been proposed that pulmonary DC expression of
the IgE receptor FcεRI is required for their mediation of on-
going HDM responses [86] and promotion of mucous meta-
plasia [87].
Th2 cell migration from the LNs to the lung tissue is
thought to predominantly involve their expression of the che-
mokine receptor CCR4, increasing responsiveness to the
chemokines CCL17 and CCL22 [88, 89]. CCL17 and
CCL22 can be produced by a range of innate cells within
the lung, including DCs [90, 91], macrophages [92] and ECs
[93], are induced by cytokines such as TSLP, IL-25, IL-33 and
IL-13 [94–96] and are often found at elevated levels during
either murine or human pulmonary allergic inflammation
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[86,91,97–99]. Importantly, although CCR4 is often consid-
ered to be particularly important for Th2 cell recruitment [53,
88], it can be expressed by a variety of other cell types [100],
including Th17 cells [101] and ILCs [102], implying that
Th17 and ILC recruitment could also involve CCL17 and
CCL22. These chemokines may also feedback to influence
activation of DCs and ECs, as both have been reported to
express CCR4 [103, 104]. Given the variety of cell types that
can express CCR4, CCL17 and CCL22, identification of the
key producers and responders will be important to better un-
derstand migration of effector CD4+ T cells to defined regions
of the lung tissue during distinct phases of allergic pulmonary
inflammation.
While the consensus would be that the majority of adaptive
priming by pulmonary DCs occurs in the secondary lymphatic
organs [105], tertiary lymphoid structures termed inducible
bronchus-associated lymphoid tissue (iBALT) can be found
in the lung during disease and may provide additional loca-
tions for DC/T cell interaction and activation [106]. In fact, it
has been suggested that iBALTmay even act as a site for naïve
T cell priming, in a process that is maintained by and requires
DCs [107, 108], as well as being a location for enhanced B cell
ac t iva t ion . Given inc reas ing awareness o f the
multifunctionality of other innate cell types such as ECs or
ILCs present in the lung tissue, it may be expected that such
cells would exert even more of an influence over the process
of DC polarisation of naïve T cells in the iBALT than in the
more remote LNs, in particular through provision of cytokines
that may impact DC functionality, or alter polarisation of
responding T cells directly.
It seems likely that ILCs may play an important accessory
role as cytokine sources to enhance immune priming in LNs
or iBALT, or influence effector or memory cell function in
tissue sites. Further, as ILCs can express MHC [109–111], it
remains possible they could act in some settings as APCs,
though whether they have the capacity to effectively take up
and process Ag, migrate to LNs and express sufficient
costimulatory molecules to activate rather than regulate
naïve T cells remains open to debate. Indeed, questions still
remain about the relevance of ILCs in general in disease set-
tings: how they are recruited, renewed or the location(s) in
vivo where they may interact with and exert their influence
over DCs. Determining these factors will be important to en-
able balanced judgement about their general importance, ei-
ther directly or indirectly, in the development of immunopa-
thology in the lung, particularly in chronic settings.
DC subsets and induction of type 2 and type 17
inflammation
Although DCs have been shown to be both sufficient and
necessary for Th2 induction in either helminth or allergic
type 2 inflammation [59, 112, 113], the specific DC
subset(s) required and the precise mechanisms they em-
ploy to promote type 2 inflammation and immunity, re-
main unclear [14,114–116]. However, some progress has
been made on this front in recent years, as the details of
DC ontogeny have been unravelled. DCs comprise a het-
erogeneous variety of cell types or ‘subsets’, which dif-
fer based on tissue location and/or expression of partic-
ular surface markers or RNA profiles. These subsets in-
clude conventional (or ‘classical’) DCs (cDCs),
plasmacytoid DCs (pDCs) and—particularly during in-
flammation—non-conventional monocyte-derived DCs
(moDCs, also sometimes called TNFα/iNOS producing
DCs, or TIP DCs) [117]. In recent years, identification of
defining transcription factors has enabled unambiguous
classification cDC and pDC subsets in both mouse and
man [118]. In the mouse, cDCs as defined by expression
of the transcription factor Zbtb46 [119, 120] can be sep-
arated into two main subsets based on expression of the
transcription factors BATF3 or IRF4, whereas pDCs ex-
press the transcription factor E2-2 [121]. Batf3 express-
ing cDCs express CD8α+ in the spleen and CD103 or
CD24 in the periphery, whereas IRF4+ cDCs express
CD11b and are negative for CD8α. In man, cDC subsets
exist expressing CD1c or CD141 in mucosal tissues that
appear to be the equivalents of murine CD11b+ and
CD8α+/CD103+ subsets respectively [122, 123], with
similar expression patterns of transcription factors such
as IRF4 in the lung [124].
In the healthy lung, the major populations of DCs to be
found are present in the tissue rather than in the airspaces.
CD103+ DCs are heavily associated with the pulmonary epi-
thelium, while the location of CD11b+ DCs is predominantly
in the underlying tissue [125, 126]. Migration studies have
shown that, in the murine lung, CD11b+ DCs preferentially
acquire and transport soluble Ag, whereas CD103+ DCs are
more adept at dealing with particulate material [127]. From
the limited ‘steady state’ human lung DC phenotyping data
available, equivalent subsets can be identified, again predom-
inantly in the tissues [122, 128].
Recently, IRF4-dependent CD11b+ cDCs have been asso-
ciated with both Th17 [124, 129] and Th2 [130, 131] response
induction and development. This diversity in CD11b+ cDC
function likely relates to the heterogeneity that exists within
this subset, and the fact that understanding of the transcrip-
tional control of this diversity is still less developed than that
of CD8α+/CD103+ cDCs or pDCs [132]. Although the pre-
cise IRF4-dependent cDC subset responsible for Th2 induc-
tion has yet to be unambiguously shown, CD11b+ cDCs that
are reliant on the transcription factor Klf4, itself downstream
of IRF4, have recently been implicated [133]. It is currently
unclear how these CD11b+ IRF4- or Klf4-dependent cDCs
relate to the CD301b+ DCs that have also been implicated in
Th2 induction against parasitic worm infection and allergic
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responses in the skin [134] and type 17 inflammation to
Streptococcus lung infection via production of IL-6 [135].
While it is becoming clear that CD11b+ cDCs may be the
dominant cDC type involved in promotion of type 2 or type 17
inflammation, the role of CD8α+/CD103+ cDCs and pDCs in
these settings is less well understood. Limited work in this
area so far suggests that while CD8α+/CD103+ cDCs are par-
ticularly adept at promotion of Th1 responses and cross pre-
sentation to and activation of CD8+ T cells, they are dispens-
able for Th2 induction [136]. Similarly, while pDCs are
characterised by their capacity to produce large amounts of
type I IFN in response to viral infection and limited APC
ability [137], they do not appear to be vital for Th2 induction
against either allergens [138] or helminths [139]. Rather, it
appears that both CD8α+/CD103+ cDCs and pDCs may in
fact help to suppress or counter-regulate type 2 inflammation
[136, 138, 140], though the precise mechanisms involved in
this are currently unclear.
DC subsets during inflammation
In bothmouse and human, there is currently a huge disconnect
in our understanding of the diversity and impact of DC subsets
during any inflammatory setting, including in allergic pulmo-
nary disease: most of our understanding in this area has been
developed through study of lung tissue in the steady state, in
the absence of overt inflammation. As more refined and
higher resolution techniques such as mass cytometry [141],
multiparameter flow cytometry and histocytometry [142] are
increasingly applied to the lung, our understanding will ex-
pand to give vital insight into the diversity, location and acti-
vation state of DCs, their interaction with other key cell types
and how this may change during disease.
What is likely, in both mouse and human, is that during
lung inflammationmore DCs can be found in the BAL and the
proportion of moDCs present in both BAL and lung tissue
increases. In murine models of eosinophilic asthma, CD11b+
DCs accumulate with effector T cells around the airways fol-
lowing allergen challenge [126]. Additionally, it is clear in
such models that CD11b+ cDCs are superseded by CD11b+
moDCs as the predominant DC subset involved in Th2 induc-
tion with increasing allergen challenge [86]. Monocytes in
general will likely play a much more dominant role in pulmo-
nary inflammation and pathology than is currently appreciat-
ed, given increasing awareness of the impact of local and
systemic inflammation on conditioning of monocytes early
in their bone marrow development that can influence their
resulting function in the periphery [143,144] and the
multifunctionality of monocytes themselves [145].
As DCs play such a pivotal role in dictating the balance of
adaptive immunity, determining in any given disease which sub-
sets predominate, and the profile of activation that they present,
may provide vital clues as to the main immunopathologic
mechanisms involved. Importantly for asthma and pulmonary
inflammation, whether and how CD11b+ cDCs or moDCs deter-
mine the balance between eosinophilic/type 2 and neutrophilic/
type 17 inflammation remains to be determined and may be of
particular relevance in situations such as fungal asthma.
Although the importance of DCs in priming and
polarisation of naïve T cells in the lung draining LNs is clear,
the role of DCs in recruitment, retention or reactivation of
pulmonary effector or memory T cells during chronic inflam-
mation is much less clear. In fact, the fundamentals of Th2 and
Th17 cells are currently poorly understood in comparison to
Th1 cells or CD8+ T cells, with little evidence that current
concepts of T cell expansion, contraction and memory
development/longevity are relevant in the context of Th2 or
Th17 cells. However, recent work using HDM-specificMHC-
II tetramers has suggested that a single exposure to HDM
generates a central memory population of CD4+ T cells that
remain in the lung to mediate AHR [146]. Further, Th2 effec-
tor cells have been shown to respond to IL-33 by exacerbating
eosinophilic inflammation without the need for APC interac-
tion [147]. Given that pulmonary disease is often chronic in
nature, additional factors to consider include the development
of Tcell hyperresponsiveness over time and whether DCsmay
play a decisive role in fine tuning of memory T cell function.
Immunogenic vs. tolerogenic roles for DCs in lung
inflammation
As well as their potent immunogenic ability, DCs can also
play a central role in regulation of inflammation and immuno-
pathology [148]. Such ‘tolerogenic’ DCs are thought to be
able to employ a variety of direct and indirect regulatory
mechanisms, including secretion of antiinflammatory cyto-
kines, induction of anergy or hyporesponsiveness and promo-
tion of peripheral or induced regulatory T cells (iTregs) [149,
150]. In the steady state, lung DCs appear less able to induce
Tregs than macrophages [151]. However, after allergen chal-
lenge, CD103+ DCs become strongly tolerogenic, producing
both retinoic acid (RA) and TGFβ to generate iTregs [152]. In
patients with COPD, tolerogenic DCs that induce IL-10+
iTregs have been identified [153], and Helicobacter pylori
modulation of allergic inflammation is dependent on DC pro-
duction of IL-10, yet independent of Tregs [154]. Given the
ability of DCs to coordinate T cell effector function, including
induction of iTregs, this is likely to have a profound impact on
immunopathology in the lung involving any kind of adaptive
component.
Interesting parallels exist between the phenotype of Th2
promoting DCs and some tolerogenic DCs, in particular a
general low level or ‘immature’ phenotype evident in either
case [114, 115]. Indeed, in some settings, Th2-inducing DCs,
through their promotion of type 2 responses that can counter-
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regulate Th1 inflammation, could be considered regulatory or
tolerogenic. As yet, a side by side comparison of Th2 vs.
tolerogenic DCs has yet to be carried out but would likely
be of real value in distinguishing mechanisms that are truly
regulatory from those that are Th2 promoting. Further, the
definition of immunogenic vs. tolerogenic features of DCs
may relate directly to developing concepts of ‘innate memo-
ry’, where ‘trained’ DCs could display enhanced pro-
inflammatory capacity, whereas ‘tolerised’DCswould instead
be regulatory, with the outcome being reduced or increased
susceptibility to some infections [155], along with more or
less severe inflammatory pathology [156]. As in other tissue
sites, the nature of the stimuli that DCs encounter in the lung
likely determines training vs. tolerance, and so immunogenic
vs. tolerogenic capacity.
DC mechanisms of T cell polarisation
Despite advances in subset identification and the general
association of CD8α+/CD103+ DCs with Th1 [157] and
CD11b+ DCs with Th17 and Th2 polarisation [124,
129–131,133,158], the specific mechanisms employed
by DCs to promote type 2 inflammation and immunity
remain unclear and a key unanswered question in the
field [14, 114, 115]. The paradigm established over the
past decades is that DC production of IL-12 is central to
their ability to promote Th1 polarisation [159], though
there are some exceptions to this general rule, such as
the costimulatory molecule CD70 compensating for Th1
induction in the absence of IL-12 in some settings [85].
In type 17 responses, DC production of IL-1α, IL-6 and
IL-23 has been strongly linked to their Th17 inductive
ability, with variable reliance on each of these mediators
depending on context, and when comparing murine and
human DCs [160–162]. In terms of DC induction of
iTregs, one cytokine that has been particularly implicat-
ed is TGFβ, and subsets of DCs can express TGFβ-
activating integrin αVβ8 to facilitate this process
[163]. In this context, as TGFβ can also act in concert
with cytokines such as IL-6 to promote Th17 induction
[160, 161], the relative balance of each cytokine at the
time of CD4+ T cell priming could result in either a
regulatory (iTreg) or an inflammatory (type 17/neutro-
philic) outcome. In murine models of HDM or OVA-
induced airway inflammation, mice with CD11c-
restricted deficiency in αvβ8 displayed reduced CD4+
T cell IL-17 production but intact γδ T cell IL-17,
iTreg and Th2 responses [78]. Together, this suggests
that the dominant role for DC expression of αVβ8 in
pulmonary inflammation is promotion of Th17 cells,
though its potential role in Th2 induction, and which
specific pulmonary DC subset(s) express this TGFβ-
activating integrin, currently remains unclear.
In contrast to Th1, Th17 and iTregs, no DC-derived
cytokine has yet been convincingly identified that is
central to their Th2 induction ability. Indeed, data so
far indicate that DCs tend to only display a limited
maturation phenotype in response to allergens or hel-
minths, with low level and non-distinctive cytokine
production or changes in mRNA profiles, making it dif-
ficult to identify candidate mechanisms for type 2 in-
duction [14, 114, 115]. While DC production of IL-4 or
IL-10 is not a fundamental requirement for Th2 induc-
tion [164–166], it has recently been suggested that DC
expression of PDL2 or IL-33, under the control of the
transcription factor IRF4, may be important for this
process [130, 131].
Although a clear DC-derived signal 3 for Th2 in-
duction remains elusive, it is becoming increasingly
clear that epigenetic mechanisms of transcriptional reg-
ulation may also play a major role in control of DC
activation and function during T cell activation and
polarisation and in allergic airway inflammation. The
deubiquitinase A20 has been shown to limit DC acti-
vation and restrain their induction of inflammatory re-
sponses [167], while the methyl-CpG-binding protein
Mbd2 is required for DC promotion of type 2 re-
sponses against either helminths or allergens [168].
This epigenetic layer of control of immune cells is
not restricted to DCs, with A20, Mbd2 or the
demethylase Jmjd3 also playing a part in control of
innate cells such as macrophages and mast cells [169,
170], as well as, in some cases, adaptive T and B cells
[171, 172]. Thus, defining the processes under the con-
trol of epigenetic regulators such as A20 and Mbd2 is
an exciting new frontier that is already leading to dis-
covery of previously unappreciated core mechanisms
that innate cells such as DCs used in promotion or
regulation of pulmonary inflammation.
Conclusions
Although lung type 2 inflammatory disease can be trig-
gered by a wide range of stimuli, DCs are centrally
involved in the initiation and direction of the adaptive
immune response and immunopathology that ultimately
determines the severity of chronic disease. A better un-
derstanding of the DC subsets involved, the mecha-
nisms that they employ and the cell types that they
interact with during promotion, maintenance or regula-
tion of inflammation in the lung will lead to the future
development of novel therapeutics to combat the dam-
aging immunopathology associated with chronic pul-
monary inflammatory disease (Fig. 1).
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